Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03434834 · ClinicalTrials.gov registry record · NA
OCT Pilot in Esophagus
A NA study of Barrett Esophagus, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT03434834: Completed NA study of Barrett Esophagus, sponsored by Duke University.
NCT03434834 is a NA study of Barrett Esophagus that has completed, run by Duke University. The registered enrollment target is 53 participants, below the 3,564-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03434834, a NA study of Barrett Esophagus, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to test a newly developed optical coherence tomography (OCT) device to determine 1) whether adequate tissue contact can be attained to acquire high quality images, and 2) to identify if these images can discern whether the imaged tissue is squamous or Barrett's Esophagus (BE) epithelium.
Primary Outcome
Percentage of imaged sites correctly categorized by OCT as squamous mucosa when compared to endoscopy.
Conditions Studied
Interventions
- DEVICE optical coherence tomography
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2020-03-25 |
| Phase | NA |
What the finished NCT03434834 record still lists
NCT03434834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 3,564-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which optical coherence tomography is the first listed.
NCT03434834 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03434834 about?
NCT03434834 is a clinical study titled "OCT Pilot in Esophagus". This is a pilot study to test a newly developed optical coherence tomography (OCT) device to determine 1) whether adequate tissue contact can be attained to acquire high quality images, and 2) to identify if these images can discern whether the imaged tissue is squamous or Barrett's Esophagus (BE) e...
What is the current status of trial NCT03434834?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2018-09-25. Estimated completion is 2020-03-25.
What conditions does trial NCT03434834 study?
This clinical trial studies the following conditions: Barrett Esophagus.
What interventions are being tested in trial NCT03434834?
The interventions under investigation include: optical coherence tomography (DEVICE).
Who is sponsoring clinical trial NCT03434834?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03434834 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03434834's enrollment target sits among peer trials
53 25th of 32 higher than 8 of 32 other Barrett Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
RECRUITING · NA
-
Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI